淋巴瘤国际预后指征对中国进展型非霍奇金氏淋巴瘤的适用性研究  

Suitability study of the international prognostic index(IPI) in aggressive nonHodgkin's lymphoma of Chinese

作　　者：林桐榆[1] 管忠震[1] 何友兼[1] 徐光川[1] 苏义顺[1] 周中梅[1] 刘冬耕[1] 黄慧强[1] 

机构地区：[1]中山医科大学肿瘤医院内科

出　　处：《癌症》1999年第3期320-323,共4页Chinese Journal of Cancer

摘　　要：目的：观察进展型ＮＨＬ国际预后指征（ＩＰＩ）对用标准方案治疗的中国进展型非霍奇金氏淋巴瘤预后的预测作用。方法：分析１９９１年－１９９３年间病理组织学和免疫组化确诊的进展型ＮＨＬ１２１例。按ＩＰＩ分组，全组分成低度危险组、低中度危险组、高中度危险组和高度危险组。结果：低危组、低中度危组、高中度组和高危组患者的ＣＲ率分别是９０６％、８０６％、７２７％和４１９％，３年无病生存率（ＤＦＳ）分别是５９１％、４７２％、３１８％和９７％。结论：ＩＰＩ对选择常规化疗疗效差的高危进展型ＮＨＬ病例的指示作用，也适用于中国的进展型ＮＨＬ。Objective: To research the international prognostic index(IPI) for predicting outcome in Chinese patients with aggressive nonHodgkin's lymphoma treatment with standard regimen. Methods: From 1991 to 1993, a total of 121 patients with histologically and immunohistochemistry proven of aggressive nonHodgkin's lymphoma were analysed.According to IPI, the patients were divided with low risk, lowintermediate risk, highintermediate risk and high risk groups.THZResults: The patients in low risk,low intermediate risk, highintermediate risk and high risk group had a completeresponse rates of 906%, 806%,727%,and 419%,respectively.The threeyear diseasefree suvival rates of the four groups were 591%,472%,318%and 97%,respectively.Conclusions:The international prognostic index should be also suitable to predict highrisk Chinese patients with aggressive nonHodgkin's lymphoma who are not effectively treated with standard regimens.

关 键 词：预后指征 IPI NHL 淋巴瘤 

分 类 号：R733.107[医药卫生—肿瘤]